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In the present legislations, the use of methods alternative to animal testing is explicitly 
encouraged, to use animal testing only 'as a last resort' or to ban it. The use of alternative 
methods to replace kinetics or repeated dose in vivo tests is a challenging issue. We propose 
here a strategy based on in vitro tests and QSAR (Quantitative Structure Activity 
Relationship) models to calibrate a dose-response model predicting hepatotoxicity. The dose 
response consists in calibrating and coupling a PBPK (Physiologically-based 
pharmacokinetic) model with a toxicodynamic model for cell viability. We applied our 
strategy to acetaminophen and compared three different ways to calibrate the PBPK model: 
only with in vitro and in silico methods, using rat data or using all available data including 
data on humans. Some estimates of kinetic parameters differed substantially among the three 
calibration processes, but, at the end, the three models were quite comparable in terms of liver 
toxicity predictions and close to the usual range of human overdose. For the model based on 
alternative methods, the good adequation with the two other models resulted from an 
overestimated renal elimination rate which compensated for the underestimation of the 
metabolism rate. Our study points out that toxicokinetics/toxicodynamics approaches, based 
on alternative methods and modelling only, can predict in vivo liver toxicity with accuracy 
comparable to in vivo based methods. 
 
Key-words: PBPK, model calibration, liver toxicity, acetaminophen, vitro-vivo extrapolation.  
 1. Introduction 
 
The promotion of alternative approaches to replace, reduce or refine animal use is present 
in all relevant EU legislations. For chemicals in general, the REACH legislation requires 
industry to evaluate the toxicity of new and existing chemicals, even those that are in use but 
have never been subject to regulatory testing, which translates into many thousands of 
chemicals to be tested. To fulfil this objective, the legislation explicitly encourages the use of 
methods alternative to animal testing, which would only be used 'as a last resort'. As far as 
cosmetics are concerned, the 7th Amendment to the Cosmetic Directive (76/768/EEC) was 
adopted in 2003. According to this directive, animal testing in the EU for cosmetic products 
had to stop immediately and a complete ban of animal testing for ingredients was due to enter 
into force by 11 March 2009. The deadline for most complex endpoints such as repeated dose 
toxicity, reproductive toxicity and toxicokinetics was set for the 11th of March 2013 but the 
directive can also accommodate an extension if alternative and validated methods are not 
available within this time framework. In parallel to the set up of a new legislation, 
considerable efforts, in particular from EU, were made to develop suitable and appropriate 
alternative methods. For instance, between 2003 and 2010, European Commission funded 
research programmes related to such development through FP6 and FP7 programmes for 
around 150 million euros (Adler et al., 2011).  
Most of the toxicological information for a chemical obtained through in vitro testing 
provides information on the dose response relationship at target cell or, more rarely, at target 
organ level. Future risk assessment is expected to focus on avoiding significant perturbations 
in toxicity pathways through in vitro assays on human cells or cell lines (Krewski et al., 
2010). To integrate the in vitro results into quantitative in vivo risk assessment, it is thus 
necessary to relate the toxicokinetics (TK) of the chemical in the body and the 
toxicodynamics at each target level (Andersen and Krewski, 2010 ; Adler et al., 2011 ; 
Louisse et al., 2012 ; Yoon et al., 2012). This can be achieved through Physiologically Based 
Toxicokinetics or Pharmacokinetics models - PBTK or PBPK- (Clewell et al., 2008). A 
PBTK model consists of a series of mathematical equations which, based on the specific 
physiology of an organism and on the physicochemical properties of a substance, are able to 
describe the absorption, distribution, metabolism and elimination (ADME) of the compound 
within this organism. The solution of these equations provides the time-course of the parent 
compound and its metabolites in the organs and allows for a sound mechanistic description of 
the kinetic processes including accumulation in tissues. 
There are only a few examples for which PBPK models were used to extrapolate in vitro 
response to in vivo hazard assessment. Rotroff et al. (2010) combined a simple PBPK model 
with in vitro bioactivity data to rank chemicals according to actual human oral exposure and 
oral exposure leading to significant activity. As for tentative to go a step further in the 
prediction, Péry et al. (2011) showed the possibility to relate in vitro and in vivo gene 
responses in macrophages following exposure to benzo(a)pyrene through PBPK modeling. 
Punt et al. (2011) proposed a few examples where PBPK models have been used to 
extrapolate in vitro toxicity results to the in vivo situation. They show that predictions of in 
vivo effects on the basis of integrated in vitro and PBPK modeling approaches are generally 
within one order of magnitude of the observed in vivo data. Among the examples, Gubbels 
van-Hal et al. (2005) attempted to predict acute toxicity and repeated dose toxicity based on 
PBPK models and cytotoxic data. In general, the predictions over-estimated the toxicity, 
which could be both due to overestimation of the effects in the in vitro systems and 
uncertainty on the toxicokinetics parameters. There are thus improvements to be made both in 
the experimental field and in the accurate calibration of toxicokinetics models. Punt et al. 
(2011) asked for more examples that provide proof of principle of deriving in vivo dose–
response curves based on in vitro assays and PBPK modeling techniques. Yoon et al. (2012) 
reviewed different quantitative in vitro to in vivo extrapolations (QIVIVE). They identified 
key elements that have to be predicted for a successful extrapolation: (i) intestinal absorption 
and pre-hepatic clearance, (ii) hepatic and extra-hepatic metabolic clearance, (iii) renal 
clearance, (iv) volume of distribution (for acute in vivo exposures). They also indicated that 
only rare examples of QIVIVE do not rely, at least partly, on in vivo data. 
In this paper, we propose a modeling framework to predict in vivo liver toxicity. The 
proposed framework is composed by a dynamic model to analyse in vitro concentration-liver 
cell viability data throughout time, and by a PBPK model to relate dose of exposure and 
concentration in the liver. As case study, this modeling framework was applied to humans 
exposed to acetaminophen, which is a pharmaceutical known for its hepatotoxicity (Jaeschke 
et al., 2011). The human PBPK model was calibrated in three different ways: i. with in vitro 
and in silico methods only, ii. by extrapolating to humans a PBPK model calibrated for rats, 
as usually performed in human toxicokinetics assessment based on animal testing, iii. or by 
using all relevant available data, including actual human data to compare the quality of the 
kinetics and effects predictions based either on animal or non-animal testing. 
 2. Materials and methods 
 
2.1. Toxicokinetic data in rats for acetaminophen 
 
Male Sprague-Dawley rats were purchased from Elevage Janvier Laboratory (Le Genet 
Saint Isle, France). They were maintained under standardized conditions (relative humidity 
55±15%, 12-h day night cycle, room temperature 22±2°C). There were five different groups 
of 16 rats, with different times of exposure per group. For each group, 14 rats were orally 
exposed to a single dose of acetaminophen in an aqueous suspension containing 
methycellulose (0,5% w/v) and Tween 80 (0,1% w/v). We selected the dose of 600 mg/kg 
which is likely to induce liver damages in some Sprague-Dawley rats after the ingestion of 
one dose (Clayton et al., 2006). The remaining 2 control rats received vehicle only. The 
volume of administration was 10 ml/kg for each animal. Individual blood sample were 
collected from the retro-orbital sinus under slight isoflurane anaesthesia at 30, 60, 120, 180 
and 240 min, then collected into plastic tubes containing lithium heparin as an anticoagulant 
and immediately centrifuged (17000 g at 4°C during 10 minutes to extract plasma). The urine 
was collected during the 24h post-exposure. Individual post-dose urine samples were 
collected from each rat into vessels which contained 0,5 ml of a 100 mg/ml solution of 
sodium azide in distilled water as an antibacterial preservative and were kept frozen at -80°C. 
The experimental protocol has been approved by the local ethical committee for animal 
research. 
Acetaminophen (APAP) metabolism mainly occurs through sulfation and glucuronidation. 
A small fraction of the drug undergoes oxidative metabolism via cytochrome P450 and is 
excreted as acetaminophen mercapturate and acetaminophen cysteine. In rats, at a dose of 320 
mg/kg, one half is excreted as acetaminophen glucuronide (one half in the bile, one half in 
urine) and one third is excreted in urine as acetaminophen sulfate (Watari et al., 1983). For 
the dose of concern in our experimental study (600 mg/kg), Hjelle and Klaasen (1984) 
showed that biliary excretion of APAP and its metabolites reached 49% (between 20.2 and 
29.3% after 4 hours), most of the compounds in the bile being glucuronide conjugate. 
Consequently, most of the analytical measurements in our experimental study focused on 
acetaminophen, acetaminophen glucuronide and acetaminophen sulfate. They were measured 
in blood and urine by PHATOPHY (Marcy-L’étoile, France) through LC/MS-MS method. In 
addition, acetaminophen mercapturate was measured in urine by the same company with the 
same analytical method to improve the accuracy of the estimation of the parameters. 
 
2.2. PBPK modelling of acetaminophen kinetics in rats 
 
 The formation of acetaminophen sulfate in rats is limited by the availability of inorganic 
sulfate, with a rate of steady-state acetaminophen sulfate formation around 33 µmol/kg/hour 
(Galinsky and Levy, 1981), which, in our study, corresponds to 10 µmol per hour. For 
moderate doses of APAP, sulfation capacity rapidly decreases to 20-30% of normal level 
(Kim et al., 1992; Liu and Klaassen, 1996). Kim et al. (2009) also showed that 18h after a 
pretreatment with a dose of APAP of 500 mg/kg, rats still had a deeply depleted capacity of 
sulfation. In contrast, there is no saturation of the cumulative excretion of the glucuronide 
conjugate from 37.5 to 600 mg/kg (Hjelle and Klaasen, 1984). We thus did not account for 
saturation of glucuronidation but accounted for saturation of sulfation, by introducing both a 
maximum velocity per µmol of available sulfate and the total quantity of available sulfates.  
 The rat PBPK model describes the kinetics of acetaminophen, and also of its main 
metabolites to compare its prediction with data available in the literature. The parameters are 
listed in Table 1 and a schematic representation available in Figure 1. The equations are the 
following: 




where Qadmin corresponds to total quantity of ingested APAP during the first minute (in µmol), 
and set to zero afterwards. Fracing correspond to the fraction of acetaminophen that can enter 
the liver and kgut to the oral absorption rate (min-1).  




with, in the organ i, Ci the concentration (of APAP, sulfate APAP or APAP glucuronide) (in 
µmol/L) and PCi the partition coefficient (of APAP, sulfate APAP or APAP glucuronide), Vi 
the volume (in L), Fi the blood flow (in L/min/kg), and Cb the concentration in blood (in 
µmol/L). The equations are more complex for liver: 
 (3) 
with QAPAPliv the total quantity of APAP in the liver, CAPAPblood the concentration of APAP in 
blood, QSULF the total quantity of sulfate APAP that has been produced (in µmol), QS the 
maximum value for this quantity (in µmol), and fup the fraction not bound to proteins. No 
resynthesis term was needed because the time-frame in the animal is short. 




with QGLUliv the total quantity of APAP glucuronide in the liver and CGLUblood the 
concentration of APAP glucuronide in blood.  
 For sulfate APAP, we have: 
 (5) 
 
with QSULFliv the total quantity of sulfate APAP in the liver and CSULFblood the concentration of 
APAP sulfate in blood.  
 Urinary excretion is assumed to occur from blood with a rate proportional to the 
concentration in the blood: 
 (6) 
 
 As we only disposed of data on mercapturate in the urine, not in blood, we used an 
equation that related directly the quantity of mercapturate eliminated in the urine and the 




 Some of the parameters of the PBPK model were fixed (see Table 1). For all rats, body 
weights (BW, in kg) and urinary volume for 24 hours (Vu, in mL) were measured. Partitions 
coefficients were calculated using the algorithm by Rodgers and Rowland (2006) with 
Simcyp simulation software version 11.1 (Simcyp Limited, Sheffield, UK). Blood to plasma 
ratio equals to 1 (Naritomi et al., 2003) and protein binding values for APAP in serum is 
known (Bailey and Briggs, 2004). The fraction of ingested APAP entering the liver was fixed 
at 0.9. It corresponds to the common total amount of excreted APAP and metabolites in rat 
after oral absorption (Brown et al., 1979). For metabolism, Km values (in µM) for glucuronide 
and sulfate formations were taken from experiments with male Wistar rats by Watari et al. 
(1983).  
 All the other parameters (rate of stomach absorption, maximum velocities for metabolism, 
and urinary excretion rates) were estimated based on our rat in vivo data (blood and urine 
measurements). This estimation was performed through the maximum likelihood method. The 
measurement errors were assumed to be independent and log-normally distributed, with a 
geometric mean equal to the PBPK model predictions and a geometric standard deviation 




where the function F(X,θ) corresponds to a PBPK model with input X and parameters θ, and 
σc is equal to 1.1. Parameters estimation and building of confidence intervals were performed 
using the MCSim software (Bois and Maszle, 1997).  
 
2.3.  Human PBPK modeling and calibration 
  
In the human model, we focused on the kinetics of acetaminophen. The equations were the 
same as for rats, except for liver, with no sulfate formation limitation expected for humans, 




We used three ways to calibrate the human PBPK model.  
The first one consisted in considering only data from methods alternative to animal testing 
(in vitro and in silico methods).  We used two tools, ACD/Labs PhysChem Suite version 
12.00 for the calculation of the octanol-water partition coefficient and pKa, and ACD/Labs 
ADME Suite version 5.0 for the calculation of human intestinal absorption and fraction 
unbound. Then, the algorithm by Rodgers and Rowland (2006) to deduce the partition 
coefficients. ACD/Labs PhysChem Suite estimates the octanol-water partition coefficient 
(logP) by a structure fragment approach; it splits the structure into fragments and searches for 
identical fragments in the internal databases, which contains well-characterized increments for 
over 500 different functional groups, together with well-characterized increments for different 
types of carbons that are not involved in any functional group as well as well-characterized 
increments for over 2,000 different types of pair-wise group interactions through aliphatic, 
aromatic and vinylic systems. It includes two different predictive algorithms – ACD/LogP 
Classic and ACD/LogP GALAS. Each prediction is provided with its reliability evaluation by 
the means of 95% confidence intervals (ACD/LogP Classic), or Reliability Index (ACD/LogP 
GALAS). From the two reliable predictions of acetaminophen LogP (ACD/LogP Classic = 
0.34; ACD/LogP GALAS = 0.54), a consensus LogP value was derived equal to 0.44. 
ACD/Labs PhysChem Suite was used to estimate acetaminophen pKa; it estimates accurate 
acid-base ionization constants (pKa values) at 25°C and zero ionic strength in aqueous 
solutions for almost any organic or inorganic structure. The accuracy of the calculations is 
typically better than ±0.2 pKa units except for highly complex structures or poorly 
characterized substituents, where the accuracy is usually within ±0.5 pKa units. The 
acetaminophen dissociation constants (Ka) for the strongest acid and base ionization centers 
were calculated equal to 9.9 (±0.1) and 1.7 ((±0.5), respectively. The Blood Brain Barrier 
Penetration ACD/ADME Suite module was used to calculate the unbound fraction in plasma. 
The BBB module provides reliable and easily interpreted predictions of passive BBB 
permeation rate (expressed as LogPS constants); it calculates steady-state distribution ratio 
between brain tissue and plasma (LogBB) and unbound (i.e., pharmacologically active) 
fraction of drug in plasma and in brain tissue. The calculated unbound fraction of 
acetaminophen in plasma tissue was equal to 0.88. 
ACD/ADME Suite was employed for the calculation of human intestinal absorption and 
fraction unbound. For human intestinal absorption it predicts the effect of a compound’s 
physicochemical properties (logKow, pKa(acid), pKa(base)) on the upper limit of its intestinal 
passive absorption via both transcellular and paracellular routes, its human jejunum 
permeability and its absorption rate. The model was built based on approximately 600 data 
points of human in vivo intestinal absorption. The acetaminophen calculated upper limit of 
intestinal passive absorption via transcellular and paracellular routes resulted equal to 99% 
and 1%, respectively; the human jejunum permeability and absorption rate resulted equal to 
4.68 ×  10 -4 cm/s and 0.032 min-1. The estimation of human oral bioavailability was obtained 
using the physiological-based pharmacokinetic model described and applied to 
acetaminophen by Paixão et al. (2012), based on in vitro and QSAR data. The fraction 
entering liver would be 1 for 1g and 0.99 for 10g. In our simulation, we kept a value of 1 for 
all doses.  
For metabolism, Km and Vmax values for glucuronide and sulfate formations were taken 
from experiments with cryopreserved human hepatocytes by Riches et al. (2009). As their 
values were expressed per number of cells, we used the conversion factor proposed by Barter 
et al. (2007) to have data expressed per g of liver. Excretion rate was estimated as in Rotroff 
et al. (2010). The rate of renal excretion was estimated by multiplying the predicted 
percentage of unbound acetaminophen in plasma by the normal adult human glomerular 
filtration rate (111 ml/min).  
The second way to calibrate the human PBPK model consisted in extrapolating from rat to 
human. We kept the same blood to plasma ratio, partition coefficients between blood and 
tissues and protein binding values that were determined for rats. The fraction of ingested 
APAP entering the liver was also adopted from experiments on rats and fixed at 0.9. Urinary 
excretion rate of acetaminophen was estimated based on the estimate for rats through 
biometric scaling (ratio of the glomerular filteration rates of the two species (Lin, 1995)). 
Metabolism parameters were scaled as in Haddad et al. (1998), i.e. same Km value and Vmax 
scaled by BW0.74.  
The third calibration was performed by fitting available human data. Critchley et al. (2005) 
measured human plasma and urine concentrations of acetaminophen and its conjugates after 
oral administration of 20 mg/kg. After 24 hours the authors found in the urine 59.9% 
glucuronide, 27.7% sulfate, 4.7% acetaminophen and 7.7% of other metabolites. Prior to 
adjustment, we converted these data into urine concentration and considered that all the 
ingested acetaminophen was in urine either as parent compound or metabolites. Critchley et 
al. (2005) also found respective plasmatic area under the curve (AUC) after 24hours of 83 
µg/mL/h with maximal plasmatic concentration (Cmax) between 14.4 and 22.9 µg/mL. Model 
adjustment was achieved by estimating the fraction of APAP entering liver, absorption rate 
and maximal velocities that would maximize the likelihood of these data (plasma AUC and 
Cmax and concentration of acetaminophen and metabolites in urine).  
 
2.4. Calibration of the in vitro dose response for HepaRG cells 
 
We used data on effects of acetaminophen on HepaRG cells which were available at the 
Joint Research Center (JRC), Ispra Italy. HepaRG cells have been shown to be a useful model 
to study mechanisms of acetaminophen hepatotoxicity in humans (McGill et al., 2011). The 
cell exposure procedure was already described in Mennecozzi et al. (2012). Briefly, a vial of 
cryo preserved Human Cell Line HepaRG was obtained from INSERM’s laboratory U522 
and a cell culture bank had been established in house at JRC. HepaRG cells were seeded at a 
density of 2.6 × 104 cells/cm2 in the growth medium composed of Williams E medium 
supplemented with 10% FCS, 100 units/mL penicillin, 100 μg/mL streptomycin, 5 μg/mL 
insulin, 2 mM glutamine and 5 × 10−5 M hydrocortisone hemisuccinate, and then further 
culturing for 2 more weeks with the same medium supplemented with 2% DMSO in 75 cm2 
culture flask. The medium was renewed every 2 to 3 days. After differentiation, HepaRG cells 
were detached by gentle trypsinization, then seeded at a density of 4-5 × 104/well in 96 well 
microtiter plates (BD Biosciences) to allow the selection of hepatocyte-like populations. This 
procedure resulted in a higher percentage of hepatic-like cells versus biliary like epithelial 
cells of the HepaRG cell culture. The cells were used for testing within one week after plate 
seeding (Rodrigues et al., 2012). 32 exposure concentrations from 3.5 × 10-8 to 0.01 M were 
tested, with one value measured per concentration. Viability was assessed after 72 h of 
exposure through a high-content analysis approach (HCA) using Cellomics ArrayScan vTi. A 
10x objective was used to collect 10 image fields per well for two fluorescence channels with 
the XF93 filter set. Cell count analysis was performed using the Target Activation 
Bioapplication v.4 from Cellomics Scan Software (Mennecozzi et al., 2012). 
 To analyze the effects data (cell population dynamics as a function of exposure 
concentration), we propose the following simple growth model: 
 (10) 
with N the number of cells, k the killing rate, C the exposure concentration and NEC the No 
Effect Concentration, i.e. the concentration threshold that a cell can be exposed to without any 
decrease of cell viability. In the equation, max refers to maximum value between the two 
terms between brackets. In the control situation, N is constant as expected for HepaRG cell 
populations. The formalism used here is similar to the DEBtox approach used in 
ecotoxicology to analyze survival data (Kooijman and Bedaux, 1996), with the main 
difference that kinetics from the medium to the cell is neglected here. This is a pragmatic 
choice as we dispose only of the value after 72 h of exposure. As in DEBtox, the aim is to 
account for the time-dependence of effects, which is the only way to relate properly in vitro 
constant exposure concentration (in vitro cell density is not sufficient here to susbtantially 
metabolize acetaminophen in a 72h period) and the time-varying liver concentration profiles 
from PBPK modelling. Parameter estimation was performed by minimizing the sum of the 
squared differences between the model predictions and the actual data.  
 
2.5. TK/TD modeling 
We coupled the PBPK models and the toxicodynamic model to calculate the expected 
dose response relating in vivo liver cell viability long after absorption of acetaminophen (10 
days in our simulations) and the dose absorbed. To achieve this, Equation 10 was 
incorporated in the toxicokinetic model with liver blood acetaminophen concentration as 
input. We thus implicitly assumed that hepatotoxicity could be related both in vitro and in 
vivo to the acetaminophen concentration in the fluid in contact with the cells. As, in fact, 
acetaminophen hepatotoxicity is related to a minor metabolite undergoing oxidative 
metabolism via cytochrome P450 and produced directly and for a short time in the liver from 
acetaminophen (N-acetyl-p-benzoquinone imine, or NAPQI), this hypothesis seems 




3.1. PBPK modeling 
The fits of the rat PBTK model to our data are presented in Figure 2 for plasma. As for 
excretion, the model predicts that more than 96% of the initial amount of acetaminophen was 
eliminated after 24 h (10% not absorbed, 41% eliminated through the bile, 45% eliminated 
through urine as sulfate conjugate (58%), glucuronide (24%), acetaminophen (9%) and other 
metabolites (9%)). Actual urine data showed a recovery of 45% in urine (sulfate conjugate 
(56%), glucuronide (26%), acetaminophen (12%) and other metabolites (6%)). Estimated 
parameters are given in Table 1. 
The parameters’ estimates for the three methods to calibrate the human PBPK are given in 
Table 2. The largest differences between estimates is related to maximum metabolism 
velocity with in vitro data largely underestimating in vivo data and for urinary excretion rate 
suggesting much lower renal filtration in vivo relative to acetaminophen than expected based 
on unbound acetaminophen in plasma. We obtained predictions of urine composition of 59% 
glucuronide, 27.5% sulfate, 4.5 % acetaminophen and 9% other metabolites (measured 
percentages were 59.9% glucuronide, 27.7% sulfate, 4.7% acetaminophen and 7.7% of other 
metabolites). Plasma acetaminophen area under the concentration curve at 24 h was close to 
the measured value (80 µg/mL/h versus between 83 and 87.6 µg/mL/h). The Cmax was 
predicted at 18.2 µg/mL (observed values between 14.4 and 22.9 µg/mL), and the peak 
concentration occurs after 60 min, as it was observed.  
 
3.2.  Dose-response modeling 
Figure 3 shows the data and the model for HepaRG cells exposed to acetaminophen. We 
estimated a NEC of 0 M and a value of 1.88 h-1 for k. The estimated EC50 is 5.1 mM, within 
the range of variation of published LC50 values, from 0.21 to 28.2 mM for human 
hepatocytes (Fey and Wrzesinski, 2012). 
Figure 4 presents the expected dose-response for the three different PBPK-TD models. 
Despite some high differences in some PBPK parameters values, the resulting dose response 
relationships do not differ substantially. The standard deviation for in vitro cell viability in 
control HepaRG responses was estimated at 4.9%. If we calculate which dose would lead to a 
significant difference (at the level 0.05) compared to control situation, we obtain respectively 
820, 690 and 500 mg/kg for the human data-based, the rat data based and the alternative 




4.1. Relevance of our PBPK models relative to other kinetics studies for rats and 
humans 
 
For rats, we estimated a maximum velocity for glucuronide formation of 5.3 µmol/min/kg. 
This is twice the value found by Watari et al. (1983) for lower exposure doses (2.76 
µmol/min/kg). Maximum velocity for sulfate formation at the start of the experiment was 
estimated at 3.5 µmol/min/kg, which is lower but close to the value from Watari et al. (1983), 
4.92 µmol/min/kg. The pool of activated sulfate was estimated at a mean value of 417 µmol. 
As hypothesized, the rate of formation of new activated sulfate (10 µmol per hour) is low 
compared to this pool, which explains the rapid saturation (half depletion time is estimated at 
95 min). The renal clearance we found (0.00031 L/min) is similar to the one measured by 
Watari et al. (1983), around 0.00035 L/min. The quantity of biliary excretion throughout time 
ranges from 9 to 43% after 4 hours, and from 27 to 57% at 24 hours. These ranges are in 
accordance with data from the literature with rats exposed to 600 mg/kg APAP (Hjelle and 
Klaasen, 1984), corresponding to 20-30% at 4 hours and 50% at 24 hours. We also performed 
kinetic simulation with our model for a low dose of exposure (50 mg/kg) to assess its ability 
to predict kinetics for concentrations far below those used in our experiments. We predicted 
that 85-95% of urinary excreted compounds would be acetaminophen sulfate, 5-15% being 
acetaminophen glucuronide. Around 10% of acetaminophen would be excreted into the bile. 
This is coherent with data measured in urine and bile (Hjelle and Klaassen, 1984; Watari et 
al., 1983) showing from 5 to 20% of biliary excretion at low doses. Our rat PBPK model 
consequently appears to be relevant relative to the data on acetaminophen kinetics available in 
the literature. 
For humans, Rawlins et al. (1977) measured the time-course of plasma concentration for 6 
volunteers after oral administration of 500, 1000 and 2000 mg acetaminophen and Schwarz et 
al. (2002) followed plasma concentration after oral ingestion of 1000 mg acetaminophen by 
40 patients. They both showed an early peak in plasma concentration (in the first hour) and 
the half-lives were between 2.3 and 2.8 hours for the Rawlins study and above 3 hours in the 
Schwarz study. In our human PBPK model, calibrated on human data, we have both the early 
peak and a half life just below 3 hours at the doses these authors tested. The ratio between 
glucuronidation and sulfation at therapeutic dose (1-1.5 mg) is estimated by the model at 2, 
which is realistic (Bales et al., 1984; Esteban et al., 1996). Thus, the PBPK model based on 
human data appears to be relevant for the purpose of our study.  
 
4.2. Comparison between the three calibrations of PBPK models 
 
The estimated parameters in Table 2 depending on the calibration method mainly differ 
relative to metabolism estimate. Clearly, rats and humans show qualitative and quantitative 
differences relative to metabolism. Mice may be a more relevant model than rats to 
understand the mechanisms of acetaminophen overdosing in humans (Jaeschke et al., 2011). 
As we found here for humans, in mice, sulfation is reduced compared to what takes place in 
rats and there is no sulfate depletion when toxicity occurs (Liu and Klaasen, 1996). In vitro 
value largely underestimated the maximum velocity, by a factor of 7 for sulfation, and of 20 
for glucuronidation. This discrepancy is not surprising since the estimation of hepatic 
clearance with in vitro system is known to vary (Chaturvedi et al., 2001). Nevertheless, this 
difference is abnormally high. In the paper by Sohlenius-Sternbeck et al. (2012), an in vitro 
raw intrinsic clearance of 1.3 µL/min/106 cells was found with cryopreserved human 
hepatocytes, with a predicted in vivo clearance of 9.5 mL/min/kg, close to the actual in vivo 
value (4 mL/min/kg). In our model, we used values in Riches et al. (2009), because we looked 
for data on sulfation and glucuronidation separately. It seems however that these values, 
which corresponds to 0.19 µL/min/106 cells, largely underestimates the in vivo metabolism 
rate.  
Excretion is overestimated through alternative methods (based on filtration rate and 
unbound fraction in blood). The difference may be due to acute renal toxicity, which is 
characterized by cellular injury primarily confined to the proximal tubule and significant 
reductions in glomerular filtration rate (Blantz, 1996).  
As for the other parameters, QSAR predictions performed well. The estimated absorption 
rate was closer to the in vivo human estimate than the one based on the extrapolation from 
rats. The estimated fraction unbound to protein (fup) and Kow, that have been used for 
calculating partition coefficients were relevant enough to obtain similar partition coefficients 
between all methods. Note also that the fup was estimated for plasma at 0.88, in the range of 
in vitro measures of acetaminophen unbound fraction in blood from 0.68 to 0.95 
(Summerfield et al., 2006; Edginton et al., 2006; Sohlenius-Sternbeck et al., 2012).  
 
4.3. Relevance of the TK/TD coupling 
 
In vivo cell viability is not an immediate endpoint to predict hepatotoxicity or hepatic 
failure. We just pointed out that a significant difference with control cell viability would be 
expected for an absorbed dose between 500 and 820 mg/kg, depending on the model selected. 
These estimates are close to the usual range of human overdose, between 150 and 500 mg/kg 
(Jaeschke et al., 2011). It is important to realize that, in this paper, effects are deduced from 
concentration at organ level in a dynamic way (a differential equation) accounting explicitly 
for the time-dependence of the occurrence of adverse effects. Usually, in TK/TD approaches, 
in vivo and in vitro effects are related through the area under the curve (AUC) of the parent or 
metabolite concentration or their maximum concentration. Using a mechanistic and dynamic 
model to relate cell exposure concentration and cell death may provide more biological 
relevance. In particular, the extrapolation between different exposure durations or from one 
dose to repeated doses becomes straightforward. Moreover, a process of cell regeneration 
could easily been incorporated. It is also clear that the more data we would have for different 
exposure durations, the more robust the dynamic model would be. Here, data on cell viability 
after 24 and 48 h of exposure would have permitted to introduce additional parameters, 
accounting for instance for acetaminophen kinetics in the cells, which would have improved 
the relevance and the potential for extrapolation of the model. A substantial improvement may 
also come from a better characterization, in vitro and in vivo of the toxic metabolic pathway. 
The production of NAPQI is a function of both the intrinsic clearance for several CYP 
isozymes as well as competitive phase II metabolism. At the moment, the PBPK/PD approach 
we used ignores the impact of potential differences in CYP activities between the HepaRG 
cells and in vivo. 
The dose-response curves obtained with the different calibrations of the human PBPK 
models did not differ substantially. The in vitro underestimation of the metabolism rate was 
partly compensated by the overestimation of the renal excretion. We performed additional 
simulations setting the renal excretion value in the PBPK model calibrated based on in vitro 
and in silico data to the same value as the two other calibrated models. In this case, for a given 
cell viability, the corresponding dose would have been divided by a factor of 3. For instance, 
in this case, the dose at which significant effects on in vivo cell viability would be expected 
was estimated at 155 mg/kg in this case.  
The application of uncertainty factors is well established in toxicological risk assessment 
worldwide. The key issue for decision making is to assess the confidence one can have in a 
toxicological data or predictions. This is even more crucial when trying to predict effects in 
vivo based on the integration of many components either from experimental or computational 
sources. A PBPK/TD model calibrated only based on alternative methods may not have the 
same relevance as an in vivo test, but the derivation of a confidence interval, even large, may 
be enough to assess protectively the safety of a compound. In the cosmetics industry, with the 
ban of animal testing, this would, at least, permit to market the ingredients with low expected 
concern based on rational risk estimation including a full characterisation of the inherent 
uncertainty. With PBPK/TD models, uncertainty should be assessed at all steps of integration 
and with all the sources. For instance, in the present study, quantifying the expected degree of 
difference between the metabolism rate estimated in vitro and the actual human one would 
have been of great interest. This process would be similar to the validation of Integrated 
Testing Strategies (ITS), in which the predictive capacity of the whole strategy may largely 
depend on the predictive capacity of each building block (De Wever et al., 2012). At the 
moment, only one in vitro toxicokinetic method is accepted at the OECD level (OECD 
guideline 428 for in vitro dermal absorption). It has been suggested that methods to assess in 
vitro protein binding, in vitro metabolism and clearance, and in vitro oral absorption should 
undergo reliability assessment with a small sample of compounds with properties relevant for 
cosmetics (Adler et al., 2011). Similarly, the same reliability assessment should also be 
applied to computational methods, such as the algorithms that predict partition coefficients 
(e.g. tissue:blood partitioning) in order to check their pertinence for the chemicals space 
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 Table 1 
Parameters of the rat PBPK model. Values are either from the literature or estimated based on 
the data we generated  
Body weight (kg) BW  measured 
Urinary volume (mL) Vu  measured 
Scaled volume of liver scVl 0.037 Haddad et al., 1998 
Scaled volume of adipose tissues scVf 0.07 Haddad et al., 1998 
Scaled volume of well perfused tissues scVwp 0.11 Haddad et al., 1998 
Scaled volume of poorly perfused tissues scVpp 0.723 Haddad et al., 1998 
Scaled volume of blood scVbl 0.06 Haddad et al., 1998 
Cardiac output (L/min/kg) Fcard 0.296 Davies and Morries, 1993 
Scaled liver blood flow scFl 0.25 Haddad et al., 1998 
Scaled adipose tissues blood flow scFf 0.07 Haddad et al., 1998 
Scaled well perfused blood flow scFwp 0.54 Haddad et al., 1998 
Scaled poorly perfused blood flow scFpp 0.14 Haddad et al., 1998 
Fraction of APAP entering liver Fracing 0.9 Brown et al., 1979 
Absorption rate from gut to stomach (min-1) kgut 0.0116 estimated 
Liver to blood APAP partition coefficient  PCl 0.774 Rodgers and Rowland, 2006 
Well perfused tissues to blood APAP partition 
coefficient  
PCwp 0.774 Rodgers and Rowland, 2006 
Poorly perfused tissues to blood APAP partition 
coefficient  
PCpp 0.66 Rodgers and Rowland, 2006 
Adipose tissues to blood APAP partition coefficient  PCf 0.25 Rodgers and Rowland, 2006 
Protein binding for APAP in liver fupAPAP 0.75 Ishii et al., 2002 
Protein binding for sulfate APAP fupSULF 0.38 Ishii et al., 2002 
Protein binding for APAPglucuronide fupGLU 1.01 Ishii et al., 2002 
Michaelis constant for APAP glucuronide formation 
(µM) 
KmG 915 Watari et al., 1983 
Michaelis constant for sulfate APAP formation (µM) KmS 109 Watari et al., 1983 
Maximum velocity for APAP glucuronide formation 
(µmol/min) 
VmaxG 5.3 estimated 
Maximum velocity for sulfate APAP formation per 
µmol sulfate (µmol/min/µmol) 
vmaxS 0.00854 estimated 
Total quantity of available sulfate (µmol) QS 417 estimated 
APAP urinary excretion rate (L/min) kAPAPkid 0.00031 estimated 
APAP glucuronide urinary excretion rate (L/min) kGLUkid 0.0031 estimated 
Sulfate APAP urinary excretion rate (L/min) kSULFkid 0.024 estimated 
Mercapturate urinary excretion rate (L/min) kMERkid 0.00028 estimated 
APAP glucuronide biliary excretion rate (L/min) kGLUbil 0.0095 estimated 
Table 2 
Parameters of the human PBPK model, depending on the method we used to calibrate it (only 
alternative methods, extrapolation from the rat model, use of human data leading to re-
estimation).  
Body weight (kg) BW 73 Fixed 
Urinary volume (mL) Vu 1500 Fixed 
Scaled volume of liver scVl 0.025 Mielke and Gundert-Remy, 2009 
Scaled volume of adipose tissues scVf 0.25 Mielke and Gundert-Remy, 2009 
Scaled volume of well perfused tissues scVwp 0.08 Mielke and Gundert-Remy, 2009 
Scaled volume of poorly perfused scVpp 0.06 Mielke and Gundert-Remy, 2009 
Cardiac output (L/min/kg) Fcard 0.089 Mielke and Gundert-Remy, 2009 
Scaled liver blood flow scFl 0.255 Mielke and Gundert-Remy, 2009 
Scaled adipose tissues blood flow scFf 0.05 Mielke and Gundert-Remy, 2009 
Scaled poorly perfused blood flow scFpp 0.22 Mielke and Gundert-Remy, 2009 
Fraction of APAP entering liver Fracing 1 
0.9 
0.95 
Paixão et al. (2012) 
Same value as for rats  
Re-estimated for humans. 




Same value as for rats 
Re-estimated for humans 
Liver to blood APAP partition coefficient  PCl 0.79 
0.77 
QSAR estimate 
Same value as for rats 





Same value as for rats 





Same value as for rats  
Adipose tissues to blood APAP partition coefficient  PCf 0.28 
0.25 
QSAR estimate 
Same value as for rats 
Protein binding for APAP in liver fupAPAP 0.88 
0.75 
QSAR estimate 
Same value as for rats 




Riches et al., 2009 
Same value as for rats 
Michaelis constant for sulfate APAP formation (µM) KmS 300 
109 
Riches et al., 2009 
Same value as for rats 






Riches et al., 2009 ; Barter et al., 
2007 
Extrapolated from rats 
Re-estimated for humans 






Riches et al., 2009 ; Barter et al., 
2007 
Extrapolated from rats 
Re-estimated for humans 
APAP urinary excretion rate (L/min) kAPAPkid 0.098 
0.016 
Calculated 
Scaled from rat model 
Mercapturate urinary excretion rate (L/min) kMERkid 0 
0.015 
Default value 
Scaled from rat model 
 Figure legends 
 
Fig. 1. Schematic presentation of the PBTK model used to describe the kinetics of 
acetaminophen and its metabolites.  
 
Fig. 2. Kinetics of acetaminophen and its two main metabolites (glucuronide and sulfate) in 
rat plasma (the data points are the measured values and the line represents the prediction for 
an individual with a median weight and urinary volume).  
 
Fig. 3. HepaRG cell viability as a function of acetaminophen exposure concentration. Points 
represent the actual data and the line represents the regression of the data with our model.  
 
Fig. 4. Predicted in vivo cell viability as a function of dose for the three different PBPK-TD 
models (plain lines: PBPK models calibrated on human data; dotted lines: PBPK model 
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